Details

Autor(en) / Beteiligte

• Bhatia, Shilpa
• Nguyen, Diemmy
• Darragh, Laurel B
• Van Court, Benjamin
• Sharma, Jaspreet
• Knitz, Michael W
• Piper, Miles
• Bukkapatnam, Sanjana
• Gadwa, Jacob
• Bickett, Thomas E
• Bhuvane, Shiv
• Corbo, Sophia
• Wu, Brian
• Lee, Yichien
• Fujita, Mayumi
• Joshi, Molishree
• Heasley, Lynn E
• Ferris, Robert L
• Rodriguez, Olga
• Albanese, Christopher
• Kapoor, Mohit
• Pasquale, Elena B
• Karam, Sana D

Titel

EphB4 and ephrinB2 act in opposition in the head and neck tumor microenvironment

Ist Teil von

• Nature communications, 2022-06, Vol.13 (1), p.3535-3535, Article 3535

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• Differential outcomes of EphB4-ephrinB2 signaling offers formidable challenge for the development of cancer therapeutics. Here, we interrogate the effects of targeting EphB4 and ephrinB2 in head and neck squamous cell carcinoma (HNSCC) and within its microenvironment using genetically engineered mice, recombinant constructs, pharmacologic agonists and antagonists. We observe that manipulating the EphB4 intracellular domain on cancer cells accelerates tumor growth and angiogenesis. EphB4 cancer cell loss also triggers compensatory upregulation of EphA4 and T regulatory cells (Tregs) influx and their targeting results in reversal of accelerated tumor growth mediated by EphB4 knockdown. EphrinB2 knockout on cancer cells and vasculature, on the other hand, results in maximal tumor reduction and vascular normalization. We report that EphB4 agonism provides no additional anti-tumoral benefit in the absence of ephrinB2. These results identify ephrinB2 as a tumor promoter and its receptor, EphB4, as a tumor suppressor in HNSCC, presenting opportunities for rational drug design.